FTRE

Fortrea Holdings Inc. (FTRE) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Fortrea Holdings Inc. is a global contract research organization (CRO) spun off from Laboratory Corporation of America Holdings (Labcorp) in June 2023. The company operates in a single reportable segment, Clinical Services. A significant strategic shift occurred in Q2 2024 with the sale of the Enabling Services Segment (Patient Access and Endpoint businesses), which is now classified as discontinued operations.

Key Financial Metrics

Note: Net Income includes a loss of $(39.1) million from discontinued operations for Q2 2024. Continuing operations net loss was $(99.3) million.

Material Changes vs. Prior Period

• Revenue Decline: Revenues from continuing operations decreased 8.6% in Q2 and 6.7% YTD compared to 2023. This was driven by an 8.3% decrease in organic revenue due to lower pass-through costs and reduced service revenue burn rates from pre-spin business wins.
• Operating Loss: The company reported an operating loss of $(50.9) million in Q2 2024, a reversal from an operating income of $31.6 million in Q2 2023. This was primarily due to a significant increase in Selling, General, and Administrative (SG&A) expenses and higher interest costs.
• SG&A Increase: SG&A expenses rose 59.7% in Q2 2024 to $156.2 million. Management attributes this to incremental costs incurred to exit the Transition Services Agreement with Labcorp and the costs of operating as a standalone entity.
• Debt Reduction: The company aggressively paid down debt, reducing long-term debt by approximately $442 million YTD. Term Loan B was reduced by $411 million in Q2 alone.
• Discontinued Operations: The sale of the Enabling Services Segment resulted in a loss on disposal of $23.2 million and a goodwill impairment of $24.0 million recognized in the first half of 2024.

Guidance, Outlook, and Risks

• Backlog: As of June 30, 2024, the company's backlog stood at $7.4 billion. Management notes that backlog is not a consistent indicator of future revenue due to contract variability and potential cancellations.
• Liquidity: The company maintains a $450 million revolving credit facility with no outstanding balance as of June 30, 2024. A new $300 million accounts receivable securitization program was initiated in May 2024, with $300 million sold by quarter-end.
• Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses identified in Q1 2024 related to insufficient resources for control activities. These weaknesses have not yet been remediated.
• Restructuring: The company recorded $10.4 million in restructuring charges in Q2 2024, part of ongoing efforts to align resources and reduce overcapacity.
• Customer Concentration: One customer accounted for 13.2% of revenues in Q2 2024. Two customers accounted for 13.6% and 11.3% of revenues YTD 2024.

Investor Verification Checklist

• Remediation Plan: Verify the progress of the remediation plan for the material weaknesses in internal controls over financial reporting, as this impacts the reliability of future financial statements.
• Organic Growth Drivers: Assess the sustainability of the revenue decline and the timeline for stabilizing organic growth following the exit from the Labcorp Transition Services Agreement.
• Debt Covenants: Confirm continued compliance with financial covenants (net leverage and interest coverage ratios) given the recent debt paydowns and operating losses.
• Discontinued Operations Impact: Review the final purchase price adjustments for the Enabling Services Segment sale to ensure the loss on disposal is fully accounted for.
• Customer Concentration: Monitor the dependency on top customers, particularly given the macroeconomic pressures in the biopharmaceutical sector.